TWI729911B - Antibiotic selection notification system and medical management system including the notification system - Google Patents
Antibiotic selection notification system and medical management system including the notification system Download PDFInfo
- Publication number
- TWI729911B TWI729911B TW109127953A TW109127953A TWI729911B TW I729911 B TWI729911 B TW I729911B TW 109127953 A TW109127953 A TW 109127953A TW 109127953 A TW109127953 A TW 109127953A TW I729911 B TWI729911 B TW I729911B
- Authority
- TW
- Taiwan
- Prior art keywords
- antibiotic
- name
- report
- processing unit
- patient
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 184
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 72
- 230000005540 biological transmission Effects 0.000 claims abstract description 23
- 238000012545 processing Methods 0.000 claims description 68
- 238000007689 inspection Methods 0.000 claims description 41
- 244000052769 pathogen Species 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 36
- 230000001717 pathogenic effect Effects 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 33
- 238000010186 staining Methods 0.000 claims description 26
- 230000002159 abnormal effect Effects 0.000 claims description 22
- 244000052616 bacterial pathogen Species 0.000 claims description 19
- 241000894007 species Species 0.000 claims description 16
- 238000004043 dyeing Methods 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000012790 confirmation Methods 0.000 claims description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 239000011651 chromium Substances 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- YRMCBQLZVBXOSJ-PCFSSPOYSA-N (e)-3-[(6r,6as)-4-hydroxy-6-methoxy-3-methyl-11-oxo-5,6,6a,7-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl]prop-2-enamide Chemical compound CO[C@H]1NC2=C(O)C(C)=CC=C2C(=O)N2C=C(\C=C\C(N)=O)C[C@@H]12 YRMCBQLZVBXOSJ-PCFSSPOYSA-N 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 13
- 229940088710 antibiotic agent Drugs 0.000 description 38
- 241000894006 Bacteria Species 0.000 description 10
- 238000007726 management method Methods 0.000 description 10
- 244000005700 microbiome Species 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 5
- 229960002682 cefoxitin Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002730 additional effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 4
- 229960001019 oxacillin Drugs 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 3
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229960003376 levofloxacin Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Accommodation For Nursing Or Treatment Tables (AREA)
Abstract
Description
本發明係關於一種通知系統,尤其是一種在收到病人檢驗報告時,即時通知醫師評估調整病人使用中之抗生素的抗生素選用通知系統,以及具有該系統的醫療管理系統。 The present invention relates to a notification system, in particular, an antibiotic selection notification system that immediately informs a physician to evaluate and adjust the antibiotics used by the patient when a patient's test report is received, and a medical management system with the system.
按,在病人之檢體報告尚未出來之前,醫師通常會先考量該病人各種主客觀條件,依據自身經驗選用當下適合該病人的抗生素予以治療;當該檢體報告出來後,檢驗科會將該檢體報告發送給醫師,使醫師依據該檢體報告評估該病人目前所採用的抗生素是否適當或是需要進行調整。 By the way, before the patient’s specimen report is released, the physician usually considers the patient’s various subjective and objective conditions, and selects the appropriate antibiotics for the patient based on his own experience. The specimen report is sent to the physician, so that the physician can evaluate whether the patient’s current antibiotics are appropriate or need to be adjusted based on the specimen report.
然而,醫師可能會因為臨床工作繁重、正在處理緊急事件或該檢體報告的發出時間不是在常規上班時間等因素,導致該醫師未能夠在第一時間檢視該檢體報告,進而造成延遲將該病人之抗生素調整為適合該病人病情的抗生素種類之情形。根據Liu VX等學者在2017年發表的研究指出,每延遲使用適當的抗生素一小時,罹患菌血症的病人之死亡率將增加9%,因此,當該病人原本使用的抗生素並非適當時,且越慢將其使用之抗生素調整至適當之抗生素,將對病人的安全造成影響。 However, the doctor may not be able to view the specimen report in the first time due to factors such as heavy clinical work, handling of emergencies, or the time when the specimen report is issued is not during regular working hours, which may cause delays in the inspection of the specimen report. The patient's antibiotics are adjusted to the type of antibiotics suitable for the patient's condition. According to a study published by Liu VX and other scholars in 2017, for every hour of delay in the use of appropriate antibiotics, the death rate of patients suffering from bacteremia will increase by 9%. Therefore, when the patient's original antibiotics are not appropriate, and The slower it is to adjust the antibiotics used to the appropriate antibiotics, it will affect the safety of patients.
此外,抗生素使用不適當,有時亦會誘發抗藥性細菌的產生,例如:使用抗菌譜範圍較窄的抗生素(低階)即可治療的疾病,卻使用抗菌譜 範圍較廣的抗生素(高階)進行治療。然而,醫生在收到檢驗報告時,可能會因為該病人原本使用的抗生素已經獲得初步療效,而不願意主動將目前使用的抗生素進行降階,或是醫師不熟悉該檢驗報告中所提到的致病菌(如:細菌或黴菌等)、各種抗生素的抗菌譜等因素,而無法做出調整抗生素的判斷,使得病人沿用原本使用的抗生素,而造成抗藥性細菌的產生。 In addition, inappropriate use of antibiotics can sometimes induce the production of drug-resistant bacteria. For example, use antibiotics with a narrow antimicrobial spectrum (low-level) to treat diseases, but use antimicrobial spectrum. A wide range of antibiotics (high-level) for treatment. However, when the doctor receives the test report, he may be unwilling to take the initiative to downgrade the current antibiotics because the original antibiotics used by the patient have already obtained preliminary effects, or the physician may be unfamiliar with the tests mentioned in the test report. Factors such as pathogenic bacteria (such as bacteria or molds), the antibacterial spectrum of various antibiotics, etc., cannot make the judgment of the adjustment of antibiotics, which makes the patient continue to use the antibiotics originally used, resulting in the production of resistant bacteria.
有鑑於此,有必要提供一種抗生素選用通知系統,以改善上述問題。 In view of this, it is necessary to provide an antibiotic selection notification system to improve the above problems.
為解決上述問題,本發明的目的是提供一種抗生素選用通知系統,係能夠在收到病人的檢驗報告時,加以即時判讀,於必要時通知醫師可替代該病人原本使用的抗生素的其他種類抗生素。 In order to solve the above-mentioned problems, the purpose of the present invention is to provide an antibiotic selection notification system, which can make immediate interpretation when receiving the patient's test report, and notify the physician of other types of antibiotics that can replace the original antibiotics used by the patient when necessary.
本發明的次一目的是提供一種抗生素選用通知系統,能夠即時判讀檢驗報告,且當判讀結果認為病人原本使用的抗生素無效或效果不佳時,提醒醫師注意。 The second objective of the present invention is to provide an antibiotic selection notification system, which can interpret the test report in real time, and remind the doctor to pay attention when the interpretation result believes that the antibiotic originally used by the patient is invalid or not effective.
本發明的又一目的是提供一種醫療管理系統,係能夠將上述抗生素選用通知系統與現有的醫院資訊系統及檢驗資訊系統進行整合者。 Another object of the present invention is to provide a medical management system that can integrate the aforementioned antibiotic selection notification system with the existing hospital information system and laboratory information system.
本發明全文所述「資料庫單元(Database Unit)」,係指將一群相關的電子資料集合並儲存在硬碟、記憶體或上述之組合,且可藉由資料庫管理系統(DBSMS)所提供的語法功能,例如新增、讀取、搜尋、更新及刪除等,對電子資料進行相關處理;該資料庫管理系統可以藉由不同資料結構方式管理電子資料,例如可以為關聯式、階層式、網狀式或物件導向式等,本發明係以關聯式資料庫管理系統為例進行以下說明,惟非用以限制本發明。 The "Database Unit" mentioned in the full text of the present invention refers to the collection and storage of a group of related electronic data in hard disk, memory or a combination of the above, and can be provided by a database management system (DBSMS) The grammatical functions of, such as adding, reading, searching, updating and deleting, etc., carry out related processing of electronic data; the database management system can manage electronic data through different data structure methods, such as relational, hierarchical, Mesh type or object-oriented type, etc. The present invention is described below by taking a relational database management system as an example, but it is not intended to limit the present invention.
本發明全文所述「儲存單元(Storage Unit)」,係指任何具有 電子資料儲存功能的電子裝置,該電子裝置可以為揮發性記憶體(volatile memory)或非揮發性記憶體(non-volatile memory)。舉例而言,該揮發性記憶體可以為SRAM或DRAM;該非揮發性記憶體可以為唯讀記憶體、快閃記憶體或硬碟,本領域中具有通常知識者可以依據運算效能、價格、體積限制或功能需求等予以選擇者。 The "Storage Unit" mentioned in the full text of the present invention refers to any An electronic device with electronic data storage function. The electronic device can be a volatile memory (volatile memory) or a non-volatile memory (non-volatile memory). For example, the volatile memory can be SRAM or DRAM; the non-volatile memory can be read-only memory, flash memory, or hard disk. Those with ordinary knowledge in the art can rely on computing performance, price, and volume. Restrictions or functional requirements, etc. to be selected.
本發明全文所述「人機介面單元(User Interface Unit)」,係指任何用以提供使用者與電腦系統之間建立聯繫、交換訊息的輸入/輸出設備的介面,例如但不限制地,該人機介面的輸入設備係可以為一鍵盤或一滑鼠,該人機介面的輸出設備係可以為一顯示器或一印表機。 The "User Interface Unit" mentioned in the full text of the present invention refers to any interface that provides input/output devices for establishing contact and exchanging messages between a user and a computer system. For example, but without limitation, the The input device of the human-machine interface can be a keyboard or a mouse, and the output device of the human-machine interface can be a display or a printer.
本發明全文所述之「處理單元(Processor Unit)」,係指任何具有資料儲存、運算及訊號產生功能的電子晶片,或具有該電子晶片的電子設備。舉例而言,該電子晶片可以為中央處理單元(CPU)、微控制器(MCU)、數位訊號處理器(DSP)、現場可程式化邏輯閘陣列(FPGA)或系統單晶片(SoC);該電子設備可以為可程式邏輯控制器(PLC)或Arduino UNO,本領域中具有通常知識者可以依據運算效能、價格、體積限制或功能需求等予以選擇者。 The "Processor Unit" mentioned in the full text of the present invention refers to any electronic chip with the functions of data storage, calculation and signal generation, or electronic equipment with the electronic chip. For example, the electronic chip can be a central processing unit (CPU), a microcontroller (MCU), a digital signal processor (DSP), a field programmable logic gate array (FPGA), or a system-on-chip (SoC); the The electronic device can be a programmable logic controller (PLC) or an Arduino UNO. Those with ordinary knowledge in the field can choose the one based on computing performance, price, size limitation, or functional requirements.
本發明全文所述之「雲端伺服器(Cloud Server)」,係利用虛擬化軟體建立,以將一個實體(裸機)伺服器劃分為數個虛擬伺服器,以供執行應用程式和資訊處理儲存;使用者可透過線上介面遠端存取該數個虛擬伺服器的功能。 The "Cloud Server" mentioned in the full text of the present invention is created by using virtualization software to divide a physical (bare metal) server into several virtual servers for application execution and information processing and storage; Users can remotely access the functions of these virtual servers through an online interface.
本發明全文所述「染色報告」,係指醫檢師將病人血液之培養瓶放入培養箱中,該培養箱具有自動監測該培養瓶內是否有微生物生長之功能,當該培養箱監測到該培養瓶中有微生物長出,則該培養箱之警示燈號會亮起,該醫檢師會從該培養瓶中抽出少量內容物進行染色,如格蘭氏染色 (Gram stain),並就觀察到之染色型態發出報告,該報告可以包含如球菌、桿菌等細菌型態及顏色。 The "staining report" mentioned in the full text of the present invention means that the medical examiner puts the culture bottle of the patient's blood into the incubator. The incubator has the function of automatically monitoring the growth of microorganisms in the culture bottle. When the incubator detects If microorganisms grow out of the culture flask, the warning light of the incubator will light up, and the medical examiner will extract a small amount of content from the culture flask for staining, such as Gram stain (Gram stain), and issue a report on the observed staining pattern. The report can include the type and color of bacteria such as cocci and bacillus.
本發明全文所述「初步報告」,係指當上述的培養瓶中具有致病性微生物時,醫檢師由該培養瓶中抽出一定量的微生物進行次培養,待培養基生長出微生物後,提取少量樣本進行菌種快速鑑定,以鑑別該微生物的完整名稱,但不包含抗生素敏感性試驗結果的報告。 The "preliminary report" mentioned in the full text of the present invention means that when there are pathogenic microorganisms in the above-mentioned culture bottle, the medical examiner extracts a certain amount of microorganisms from the culture bottle for secondary culture, and then extracts the microorganisms after the culture medium grows. A small number of samples are quickly identified to identify the full name of the microorganism, but does not include the report of the results of the antibiotic susceptibility test.
本發明全文所述「最終報告」,係指提取上述培養基所生長出之微生物,並利用如Vitek2等自動化儀器,除鑑定出該微生物之完整名稱外,更對該微生物進行抗生素敏感性試驗,以獲得該微生物對何種抗生素有效,對何種抗生素無效的完整報告。 The "final report" mentioned in the full text of the present invention refers to the extraction of microorganisms grown from the above-mentioned culture medium, and the use of automated instruments such as Vitek2 to identify the full name of the microorganism, and to conduct antibiotic susceptibility tests on the microorganism to Obtain a complete report on which antibiotics the microorganism is effective against and which antibiotics are ineffective.
本發明全文所述「不適當」,係指依據過往文獻、本土流行病學資料、以及專家之經驗,判斷現階段所具有之檢驗報告後,認為一抗生素對一菌種之治療效果有很高的機率為不佳或無效。 The "inappropriate" mentioned in the full text of the present invention means that an antibiotic is considered to have a high therapeutic effect on a bacterial species after judging the current inspection report based on past literature, local epidemiological data, and expert experience The probability is poor or ineffective.
本發明全文所述「可能適當」,係指依據過往文獻、本土流行病學資料、以及專家之經驗,判斷現階段所具有之檢驗報告後,認為無法顯示一抗生素對一菌種之治療效果為不適當。 The “probably appropriate” mentioned in the full text of the present invention means that based on past literature, local epidemiological data, and expert experience, after judging the current inspection report, it is considered that the therapeutic effect of an antibiotic on a bacterial species cannot be shown to be Inappropriate.
本發明全文所述「不確定」,係指依據過往文獻、本土流行病學資料、以及專家之經驗,判斷現階段所具有之檢驗報告後,無法判定該菌種是否存有致病性,或無法判定一抗生素對一菌種之治療效果為不適當或可能適當。 The "uncertain" mentioned in the full text of the present invention means that it is impossible to determine whether the strain is pathogenic after judging the current inspection report based on past literature, local epidemiological data, and expert experience, or It cannot be determined that the therapeutic effect of an antibiotic on a bacterial species is inappropriate or possibly appropriate.
本發明全文所記載的元件及構件使用「一」或「一個」之量詞,僅是為了方便使用且提供本發明範圍的通常意義;於本發明中應被解讀為包括一個或至少一個,且單一的概念也包括複數的情況,除非其明顯意指其他意思。 The elements and components described in the full text of the present invention use the quantifiers "one" or "one" for convenience and to provide the general meaning of the scope of the present invention; in the present invention, it should be construed as including one or at least one, and single The concept of also includes the plural, unless it clearly implies other meanings.
本發明的抗生素選用通知系統,包含:一資料庫單元,用以儲存一染色對應表、一初步對應表及數個分階對應表,該染色對應表用以記錄數個病菌型態,以及相對於各該病菌型態的至少一抗生素名稱,且該抗生素名稱之抗生素的適當性為不適當,該初步對應表用以記錄數個菌種名稱、相對於各該菌種名稱的數個抗生素名稱,以及各該抗生素名稱之抗生素對於治療該菌種名稱之一種致病菌的適當性,各該分階對應表用以記錄一病菌名稱、一檢體種類、相對於該病菌名稱的至少一抗生素名稱,且該抗生素名稱之抗生素的適當性係為可能適當,以及該至少一抗生素名稱之抗生素的一抗生素級別;一人機介面單元,用以輸入及顯示病人一藥囑、一染色報告、一初步報告及一最終報告,該藥囑具有該病人使用中之抗生素的一抗生素藥名,該最終報告具有一致病菌種最終名稱;一無線傳輸單元,用以傳輸電子訊號;及一處理單元,電性連接該資料庫單元、該人機介面單元及該無線傳輸單元,該處理單元透過接收到該染色報告,以取得一致病菌型態,該處理單元確認該染色對應表中,是否具有該致病菌型態與該抗生素藥名的配對,若確認結果為是,則發送一警告訊號至一聯鉻裝置,以供提醒醫師對該病人所使用中之抗生素進行調整,並對記載於該藥囑的抗生素名稱進行修改,該處理單元透過接收到該初步報告,以取得一致病菌種初步名稱,該處理單元比對該初步對應表中,是否具有該致病菌種初步名稱與該抗生素藥名,且該抗生素藥名之抗生素對於治療具有該致病菌種初步名稱之一種致病菌的適當性為不適當的配對,若比對結果為是,則發送另一警告訊號至該聯鉻裝置以供提醒醫師,並對記載於該藥囑的抗生素名稱進行修改,該處理單元接收到該最終報告時,依據該致病菌種最終名稱及該最終報告中的一抗生素敏感性報告,由該初步對應表中取得一抗生素名稱,且該抗生素名稱之抗生素對於治療該致病菌種最終名稱之一種致病菌之適當性為可能適當,該處理單元由該分階對 應表中取得抗生素級別低於該抗生素名稱之抗生素的一替代抗生素,該處理單元發送包含該至少一替代抗生素之抗生素名稱的一通知訊號至該聯鉻裝置,以供醫師評估是否將該病人使用中之抗生素調整為該替代抗生素。 The antibiotic selection notification system of the present invention includes: a database unit for storing a staining correspondence table, a preliminary correspondence table, and a plurality of hierarchical correspondence tables. The staining correspondence table is used to record a plurality of pathogen types and relative At least one antibiotic name in each pathogen type, and the appropriateness of the antibiotic name of the antibiotic name is inappropriate, the preliminary correspondence table is used to record the names of several bacterial species, and the names of several antibiotics relative to each of the bacterial species names , And the suitability of the antibiotics of each antibiotic name for the treatment of a pathogen of the bacteria name, each of the hierarchical correspondence tables is used to record a pathogen name, a specimen type, and at least one antibiotic relative to the pathogen name Name, and the appropriateness of the antibiotic of the antibiotic name is possibly appropriate, and the antibiotic level of the antibiotic of the at least one antibiotic name; a human-computer interface unit for inputting and displaying a patient’s prescription, a staining report, and a preliminary A report and a final report, the drug order has an antibiotic drug name of the antibiotic being used by the patient, and the final report has the final name of the same disease species; a wireless transmission unit for transmitting electronic signals; and a processing unit, electrical Connecting the database unit, the human-machine interface unit and the wireless transmission unit, the processing unit receives the staining report to obtain a consistent pathogen pattern, the processing unit confirms whether the staining correspondence table contains the pathogen Matching the type and the name of the antibiotic, if the confirmation result is yes, a warning signal will be sent to a bichromium device to remind the doctor to adjust the antibiotic used by the patient, and to check the information recorded in the drug order The antibiotic name is modified, the processing unit receives the preliminary report to obtain a consistent initial name of the pathogenic species, the processing unit compares the preliminary corresponding table with whether the initial name of the pathogenic bacterial species and the antibiotic drug name exist, and The antibiotic of the antibiotic drug name is inappropriate for the treatment of a pathogen with the initial name of the pathogenic species. If the result of the comparison is yes, another warning signal will be sent to the bichromium device for Remind the physician and modify the name of the antibiotic recorded in the drug order. When the processing unit receives the final report, it will respond based on the final name of the pathogenic bacteria and an antibiotic susceptibility report in the final report. An antibiotic name is obtained in the table, and the antibiotic of the antibiotic name is probably appropriate for treating a pathogenic bacteria of the final name of the pathogenic bacteria. The processing unit is determined by the level A substitute antibiotic with an antibiotic grade lower than the antibiotic name should be obtained from the table, and the processing unit sends a notification signal containing the antibiotic name of the at least one substitute antibiotic to the bichromium device for the physician to evaluate whether to use the patient The antibiotic in it is adjusted to the replacement antibiotic.
本發明的醫療管理系統,包含:上述抗生素選用通知系統;一雲端伺服器,耦接該無線傳輸單元;一醫囑系統,耦接該雲端伺服器,該醫囑系統用以產生該病人之藥囑,並將該藥囑發送至該人機介面單元;及一檢驗系統,耦接該雲端伺服器,該檢驗系統用以產生該染色報告、該初步報告及該最終報告,並將該染色報告、該初步報告及該最終報告發送至該人機介面單元。 The medical management system of the present invention includes: the aforementioned antibiotic selection notification system; a cloud server coupled to the wireless transmission unit; a medical order system coupled to the cloud server, and the medical order system is used to generate the patient's medicine order, And send the drug order to the man-machine interface unit; and an inspection system, coupled to the cloud server, the inspection system is used to generate the dyeing report, the preliminary report and the final report, and the dyeing report, the The preliminary report and the final report are sent to the man-machine interface unit.
據此,本發明的抗生素選用通知系統及具有該系統的醫療管理系統,係能夠在該人機介面單元接收到病人之最終報告時,判斷該病人使用中之抗生素是可能適當的,並藉由整合該染色對應表、該初步對應表及該分階對應表,取得抗生素級別低於該抗生素且具有可能適當效果的一替代抗生素,該處理單元依據該無線傳輸單元,將該替代抗生素的名稱發送至醫師的聯鉻裝置,以供醫師將該病人使用中之抗生素調整為該替代抗生素。如此,本發明係可以達到即時通知醫師其所照護的病人使用中之抗生素的治療效果為不適當、縮短病人之檢驗報告發出至醫師調整用藥的時間差、降低誘發致病菌抗藥性細菌產生之機會、及提升醫療照護品質等功效。 Accordingly, the antibiotic selection notification system and the medical management system with the system of the present invention can determine that the antibiotic used by the patient is appropriate when the human-machine interface unit receives the patient’s final report, and by Integrate the dyeing correspondence table, the preliminary correspondence table, and the graded correspondence table to obtain an alternative antibiotic with an antibiotic grade lower than the antibiotic and possibly an appropriate effect, and the processing unit sends the name of the alternative antibiotic according to the wireless transmission unit To the doctor's bichromium device for the doctor to adjust the antibiotic used by the patient to the substitute antibiotic. In this way, the present invention can immediately notify the doctor that the treatment effect of antibiotics in the patient under care is inappropriate, shorten the time difference between the patient’s test report and the doctor’s adjustment of medication, and reduce the chance of inducing pathogenic bacteria to produce resistant bacteria. , And improve the quality of medical care and other functions.
其中,該處理單元可以將該醫囑、該染色報告、該初步報告及該最終報告,以一使用者介面顯示於該人機介面單元,該使用者介面可以具有記錄該病人之檢驗狀態的至少一資料欄位,該檢驗狀態可以分為一正常狀態及一不正常狀態,該處理單元可以檢查記錄於各該資料欄位的檢驗狀態是否為該不正常狀態,若檢查結果為是,則該處理單元可以對記載為該不正常狀態的資料欄位進行標註。如此,具有提供醫護人員以該人機介面單元查看 標註於該使用者介面的檢驗狀態是否出現異常警示通知的功效。 Wherein, the processing unit can display the medical order, the dyeing report, the preliminary report, and the final report on the human-machine interface unit with a user interface, and the user interface can have at least one recording status of the patient In the data field, the inspection state can be divided into a normal state and an abnormal state. The processing unit can check whether the inspection state recorded in each data field is the abnormal state. If the inspection result is yes, then the processing The unit can mark the data field recorded as the abnormal state. In this way, it is possible to provide medical staff to view with the human-machine interface unit Whether the inspection status marked on the user interface has the function of an abnormal warning notification.
其中,該處理單元自動判斷該檢驗狀態是否由該不正常狀態轉變為該正常狀態,若判斷結果為是,則該處理單元自動將記載為不正常狀態之資料欄位的標註解除。如此,具有降低醫護人員工作負擔的功效。 Wherein, the processing unit automatically judges whether the inspection state is changed from the abnormal state to the normal state, and if the judgment result is yes, the processing unit automatically cancels the labeling of the data field recorded as the abnormal state. In this way, it has the effect of reducing the workload of medical staff.
〔本發明〕 〔this invention〕
1:資料庫單元 1: Database unit
2:人機介面單元 2: Human-machine interface unit
3:無線傳輸單元 3: Wireless transmission unit
4:處理單元 4: processing unit
S1:抗生素選用通知系統 S1: Antibiotic selection notification system
S2醫囑系統 S2 Medical Order System
S3:檢驗系統 S3: Inspection system
C:雲端伺服器 C: Cloud server
M:電腦主機 M: computer host
UI:使用者介面 UI: User interface
〔第1圖〕本發明抗生素選用通知系統的一較佳實施例之系統方塊圖。 [Figure 1] A system block diagram of a preferred embodiment of the antibiotic selection notification system of the present invention.
〔第2圖〕本發明醫療管理系統的一較佳實施例的系統架構圖。 [Figure 2] A system architecture diagram of a preferred embodiment of the medical management system of the present invention.
為讓本發明之上述及其他目的、特徵及優點能更明顯易懂,下文特舉本發明之較佳實施例,並配合所附圖式,作詳細說明如下:請參照第1圖所示,其係本發明抗生素選用通知系統S1的一較佳實施例,係可應用於一電腦主機,該系統係包含一資料庫單元1、一人機介面單元2、一無線傳輸單元3及一處理單元4,該資料庫單元1、該人機介面單元2及該無線傳輸單元3電性連接該處理單元4。
In order to make the above and other objects, features and advantages of the present invention more comprehensible, the preferred embodiments of the present invention will be described in detail in conjunction with the accompanying drawings as follows: Please refer to Figure 1. It is a preferred embodiment of the antibiotic selection notification system S1 of the present invention, which can be applied to a computer host. The system includes a
請一併參照第1圖所示,該資料庫單元1可以為SQLite、Microsoft SQL Server、MySQL、SQL Server、MS Access、ORACLE或DB2等資料庫,該資料庫單元1用以儲存一染色對應表、一初步對應表及數個分階對應表,該染色對應表、該初步對應表及各該分階對應表皆為一電子表格。其中,該染色對應表用以記錄數個病菌型態,以及相對於各該病菌型態的至少一抗生素名稱,且該抗生素名稱之抗生素的適當性為「不適當」,即該抗生素用以治療具有該病菌型態之一種致病菌(如:細菌或黴菌)的治療效果係
為無效或效果不佳的。
Please also refer to Figure 1. The
具體而言,該資料庫單元1可以位於該電腦主機的一儲存單元中,該染色對應表可以具有一病菌型態欄位及一抗生素名稱欄位,該病菌型態欄位用以記錄該數個病菌型態,該抗生素名稱欄位用以記錄相對於各該病菌型態的至少一抗生素名稱,且該至少一抗生素名稱之抗生素的適當性係為「不適當」,該染色對應表可以如下列表一所示:
該初步對應表用以記錄數個菌種名稱、相對於各該菌種名稱的數個抗生素名稱,以及各該抗生素名稱之抗生素對於治療該菌種名稱之一種致病菌的適當性,在本實施例中,該適當性係分為「可能適當」、「不適當」及「不確定」。具體而言,該初步對應表可以具有一菌種名稱欄位、一抗生素名稱欄位及一適當性欄位,該菌種名稱欄位用以記錄該數個菌種名稱,該抗生素名稱欄位及該適當性欄位,係分別用以記錄相對於各該菌種名稱的數個
抗生素名稱及其適當性,該初步對應表可以如下列表二所示:
該數個分階對應表用以分別記錄一病菌名稱、一檢體種類、相對於該病菌名稱的至少一抗生素名稱,且該抗生素名稱之抗生素的適當性係為「可能適當」,以及該至少一抗生素名稱之抗生素的一抗生素級別,在本實施例中,該檢體種類係可以分為血液及腦脊髓液兩種。具體而言,各該分階對應表可以具有一病菌名稱欄位、一檢體種類欄位、一抗生素名稱欄位及一抗生素分階欄位,該病菌名稱欄位用以記錄該病菌名稱,該檢體種類欄位用以記錄該檢體種類、該抗生素名稱欄位用以記錄相對於該病菌名稱的至少一抗生素名稱,且該抗生素名稱之抗生素的適當性係為「可能適當」,以及該抗生素分階欄位用以記錄該抗生素級別。當該病菌名稱為綠膿桿菌,且檢體種類為病人血液時,該分階對應表可以如下列表三所示:表三:分階對應表
該人機介面單元2具有輸入及顯示等功能,例如可以為一觸控式螢幕或一顯示器與一輸入模組(如:鍵盤、滑鼠)的組合。該人機介面單元2用以供輸入及顯示病人之一藥囑、一染色報告、一初步報告及一最終報告,該藥囑具有該病人使用中之抗生素的一抗生素藥名,較佳地,該藥囑還具有該病人的一看診科別、一病房號、一病歷號及一姓名等個人資訊。該病人之藥囑係可以由醫院的一醫院資訊系統(Hospital Information System,HIS)取得,並可由該醫院資訊系統自動將該醫囑發送至該人機介面單元2,亦可由使用者手動輸入,係本領域中具有通常知識者可以理解,在此不多加贅述。
The human-
習知檢驗流程,係可以順序包含一染色報告、一初步報告及一最終報告,該染色報告中具有一致病菌型態;該初步報告中具有一致病菌種
初步名稱;該最終報告中具有一致病菌種最終名稱及一抗生素敏感性試驗報告。較佳地,該染色報告、該初步報告及該最終報告還各具有一檢驗項目及一檢驗狀態等檢驗資訊。詳言之,該病人之染色報告、初步報告及最終報告係可以由醫院的一檢驗資訊系統(Laboratory Information System,LIS)取得,並可由該檢驗資訊系統自動將該染色報告、該初步報告及該最終報告發送至該人機介面單元2,亦可由使用者手動輸入,係本領域中具有通常知識者可以理解,在此不多加贅述。
The conventional inspection process can include a staining report, a preliminary report and a final report in sequence. The staining report has the same type of bacteria; the preliminary report has the same type of disease
Preliminary name; the final report contains the final name of the same disease species and an antibiotic susceptibility test report. Preferably, the dyeing report, the preliminary report and the final report also each have inspection information such as an inspection item and an inspection status. In detail, the staining report, preliminary report and final report of the patient can be obtained from a laboratory information system (LIS) of the hospital, and the staining report, preliminary report and the final report can be automatically obtained by the laboratory information system. The final report is sent to the man-
該無線傳輸單元3用以傳輸電子訊號,該無線傳輸單元3係可以為4G、5G、WiFi或WLAN等無線傳輸模組,惟不以此為限。
The
該處理單元4電性連接該資料庫單元1、該人機介面單元2及該無線傳輸單元3,該處理單元4透過接收到一染色報告,以取得一致病菌型態,該處理單元4確認該染色對應表中,是否具有該致病菌型態與記載於該藥囑之抗生素藥名的配對,若確認結果為否,即表示病人使用中之抗生素之適當性為「可能適當」或「不確定」,則該處理單元4可以不需進行額外作動;若確認結果為是,即表示病人使用中之抗生素之適當性為「不適當」,該處理單元4可以透過該無線傳輸單元3發送一警告訊號至一聯鉻裝置,以供提醒醫師(臨床醫師)可以對其照護的該病人所使用中之抗生素進行調整,並對記載於該藥囑的抗生素名稱進行修改。舉例而言,該聯鉻裝置可以為一個人數位助理(PDA)、一智能手機或一平板;該處理單元4係可以透過發送簡訊方式,將該警告訊號發送至該聯鉻裝置。
The
該處理單元4透過接收到一初步報告,以取得一致病菌種初步名稱,該處理單元4比對該初步對應表中,是否具有該致病菌種初步名稱與記載於該藥囑之抗生素藥名,且該抗生素藥名之抗生素對於治療具有該致病菌種初步名稱之一種致病菌的適當性為不適當的配對,若比對結果為否,則
該處理單元4可以不需進行額外作動;若比對結果為是,則該處理單元4可以透過該無線傳輸單元3發送另一警告訊號至一聯鉻裝置,以供提醒醫師可以對其照護的該病人所使用中之抗生素進行調整,並對記載於該藥囑的抗生素名稱進行修改。
The
該處理單元4接收到一最終報告時,係可以依據該致病菌種最終名稱及該最終報告中的一抗生素敏感性報告,以由該初步對應表中取得一抗生素名稱,且該抗生素名稱之抗生素對於治療該致病菌種最終名稱之一種致病菌之適當性為可能適當。該處理單元4可以由該分階對應表中取得抗生素級別低於該抗生素名稱之抗生素的一替代抗生素,該處理單元4可以透過該無線傳輸單元3發送包含該至少一替代抗生素之抗生素名稱的一通知訊號至一聯鉻裝置,以供醫師將該病人使用中之抗生素調整為該替代抗生素。
When the
本發明的抗生素選用通知系統S1,該處理單元4係能夠將該病人之醫囑、染色報告、初步報告及最終報告以一使用者介面UI顯示於該人機介面單元2。具體而言,該使用者介面UI係可用以查詢並顯示病人的個人資訊及檢驗資訊,在本實施例中,該使用者介面UI具有一看診科別欄位、一病房號欄位、一病歷號欄位、一姓名欄位、一檢驗項目欄位及一檢驗狀態欄位等資料欄位,該些資料欄位用以各別顯示該病人之看診科別、病房號、病歷號、姓名、檢驗項目及檢驗狀態。
In the antibiotic selection notification system S1 of the present invention, the
該檢驗狀態係可以分為一正常狀態及一不正常狀態,在本實施例中,該正常狀態具有「已使用適當抗生素」、「檢核時病人已死亡」、「檢核時病人已離院」、「醫師提出停止檢核」、「未達監測標準」及「解除監測」等狀態;該不正常狀態具有「染色報告用藥警示」、「初步報告用藥警示」及「最終報告用藥警示」等狀態。 The inspection state can be divided into a normal state and an abnormal state. In this embodiment, the normal state includes "appropriate antibiotics used", "patient has died at the time of inspection", and "patient has been discharged from the hospital at the time of inspection". ”, “Doctor’s request to stop the inspection”, “Failure to meet the monitoring standard” and “Release the monitoring”; the abnormal state includes “Dyeing report medication warning”, “Preliminary report medication warning” and “Final report medication warning”, etc. status.
該處理單元4係可以自動檢查該檢驗狀態是否為一不正常狀
態,若檢查結果為是,則該處理單元4係可以自動對記載為該不正常狀態的資料欄位進行標註,以和記載為該正常狀態的資料欄位作出區隔;若檢測結果為否,則該處理單元4可以不需進行額外作動。又,該處理單元4係可以自動判斷該檢驗狀態是否由該不正常狀態轉變為該正常狀態,若判斷結果為是,則該處理單元4係可以自動將記載為不正常狀態之資料欄位的標註解除;若判斷結果為否,則該處理單元4可以不需進行額外作動。
The
舉例而言,該處理單元4係可以將各該檢驗狀態的資料欄位預先設定為透明底色,並檢查各該資料欄位所記載的檢驗狀態是否為該不正常狀態,若檢查結果為是,則該處理單元4係可以將記載為該不正常狀態的資料欄位,由透明底色改為其他顏色的底色,以提醒護理人員多加注意,在本實施例中,該處理單元4係將透明底色改為紅色底色,惟不以此為限。
For example, the
此外,該處理單元4判斷各該資料欄位所記載的檢驗狀態,是否由該不正常狀態轉變為該正常狀態,若判斷結果為是,則該處理單元4係可以將記載為該不正常狀態之資料欄位,由紅色底色改回透明底色,以解除對護理人員的提醒。
In addition, the
本發明抗生素選用通知系統S1之使用者介面UI係可以為三層式架構(3-tier architecture),並採用MVC軟體架構建構而成。具體而言,係將該使用者介面UI分為一模型(Model)部分、一視圖(View)部份及一控制器(Controller)部分,其中,該模型部分用以封裝與應用程式的業務邏輯相關的資料以及對資料的處理方法,該視圖部分係能夠實現資料有目的的顯示,並可存取相對應的模型,該控制器部分用於控制應用程式的流程,並處理事件以做出回應,此外,該模型部分、該視圖部份及該控制器部分之間如何協同運作,係屬於本發明相關領域中的通常知識,在此不多贅述。 The user interface UI of the antibiotic selection notification system S1 of the present invention can be a 3-tier architecture and constructed using MVC software architecture. Specifically, the user interface UI is divided into a model part, a view part and a controller part. The model part is used to encapsulate the business logic of the application Relevant data and the processing method of the data. The view part can realize the purposeful display of the data and can access the corresponding model. The controller part is used to control the flow of the application and process events to respond In addition, how the model part, the view part, and the controller part cooperate with each other is a common knowledge in the relevant field of the present invention, so I won’t repeat it here.
請參照上述表一至表三,本發明抗生素選用通知系統S1在使 用時,若醫師評估病人係因左足蜂窩性組織炎而引起發燒症狀,可能會先以經驗性治療(empirical treatment)方式,開立oxacillin抗生素供該病人服用,並同時將該病人之血液檢體送至設置有該檢驗資訊系統之檢驗室進行檢驗。 Please refer to Table 1 to Table 3 above, the antibiotic selection notification system S1 of the present invention is in use When it is used, if the doctor evaluates that the patient has a fever caused by cellulitis of the left foot, he may first prescribe oxacillin antibiotics for the patient to take with empirical treatment, and at the same time the patient’s blood sample Send to the inspection room with the inspection information system for inspection.
當該人機介面單元2取得該病人之染色報告,且該染色報告中所提及的一致病菌型態為革蘭氏陰性桿菌時,該處理單元4在該染色對應表中確認到具有革蘭氏陰性桿菌與oxacillin抗生素的配對,藉此,該處理單元4發送一警告訊號至一聯鉻裝置,以提醒該醫師調整該病人使用中的oxacillin抗生素。隨後,該醫師在收到該警告訊號後,將該病人所使用的oxacillin抗生素調整為對治療革蘭氏陰性桿菌可能具有療效的cefoxitin抗生素。
When the human-
當該人機介面單元2取得該病人之初步報告,且該初步報告中提到該革蘭氏陰性桿菌係為綠膿桿菌時,該處理單元4可以在該初步對應表中得知,cefoxitin抗生素對於綠膿桿菌的適當性係為「不適當」,即cefoxitin抗生素對於綠膿桿菌的治療效果係為無效或效果不佳的,藉此,該處理單元4再一次發送一警告訊號至該聯鉻裝置,以提醒該醫師調整該病人使用中的cefoxitin抗生素。隨後,該醫師在收到該警告訊號後,將該病人所使用的cefoxitin抗生素調整為對治療綠膿桿菌可能具有療效的levofloxacin抗生素。
When the human-
當該人機介面單元2取得該病人之最終報告時,該處理單元4可以依據記載於該最終報告中的致病菌種最終名稱(即,綠膿桿菌),以及該最終報告中的抗生素敏感性報告,以由該初步對應表中取得一抗生素名稱,且該抗生素名稱之抗生素(即,levofloxacin抗生素)對於治療該致病菌種最終名稱之一種致病菌之適當性為可能適當。詳言之,記錄於該初步對應表中,相對於該致病菌種最終名稱的抗生素名稱之抗生素的適當性係為可能適當、不適當及不確定的其中一個,在收到該最終報告後,該抗生素之適當性可能會因為該抗生素敏感性報告,而轉變成剩餘兩個的其中一個,亦有可能不會
變化;因此,無法直接參照該初步對應表,以確認該病人使用中之抗生素的治療效果為有效的。
When the human-
該處理單元4可以由該分階對應表中取得抗生素級別低於該抗生素名稱之抗生素(即,levofloxacin抗生素)的一替代抗生素(例如:piperacillin抗生素);該處理單元4可以透過該無線傳輸單元3發送包含該至少一替代抗生素之抗生素名稱的一通知訊號至該聯鉻裝置,以供醫師將該病人使用中之抗生素調整為該替代抗生素。
The
請參照第2圖所示,其係本發明醫療管理系統的一較佳實施例,係包含一雲端伺服器C、該抗生素選用通知系統S1、一醫囑系統S2及一檢驗系統S3,該抗生素選用通知系統S1、該醫囑系統S2及該檢驗系統S3分別耦接該雲端伺服器C。 Please refer to Figure 2, which is a preferred embodiment of the medical management system of the present invention, which includes a cloud server C, the antibiotic selection notification system S1, a doctor order system S2, and a testing system S3. The antibiotic selection The notification system S1, the medical order system S2, and the inspection system S3 are respectively coupled to the cloud server C.
該抗生素選用通知系統S1係以該無線傳輸單元3耦接該雲端伺服器C,以與該醫囑系統S2及該檢驗系統S3協同作業。該雲端伺服器C係可以為一私有雲(Private Cloud)、一社群雲(Community Cloud)或一混合雲(Hybrid Cloud),惟不以此為限。
The antibiotic selection notification system S1 is coupled to the cloud server C via the
具體而言,該資料庫單元1係可以位於一電腦主機M的一儲存單元中;該人機介面單元2電性連接該電腦主機M,並用以顯示該使用者介面UI;該無線傳輸單元3係可以位於該電腦主機M中,並可耦接該雲端伺服器C;該處理單元4係可以位於該電腦主機M中且電性連接該儲存單元,以存取記錄於該資料庫單元1中的染色對應表、初步對應表、分階對應表及第四表格。
Specifically, the
該醫囑系統S2耦接該雲端伺服器C,該醫囑系統S2用以產生該病人之藥囑,該藥囑可以經由該雲端伺服器C發送至該抗生素選用通知系統S1,或是可以透過外接式存取媒介輸入至該抗生素選用通知系統S1,以供
該處理單元4將該藥囑呈現於該使用者介面UI並顯示於該人機介面單元2,在本實施例中,該醫囑系統S2係為一醫院資訊系統(HIS)。
The medical order system S2 is coupled to the cloud server C. The medical order system S2 is used to generate the patient's medicine order. The medicine order can be sent to the antibiotic selection notification system S1 via the cloud server C, or can be connected via an external The access medium is input to the antibiotic selection notification system S1 for
The
該檢驗系統S3耦接該雲端伺服器C,該檢驗資訊S3用以產生該染色報告、該初步報告及該最終報告等檢驗報告,並將該染色報告、該初步報告及該最終報告經由該雲端伺服器C發送至該抗生素選用通知系統S1,或是可以透過外接式存取媒介輸入至該抗生素選用通知系統S1,並顯示於該人機介面單元2,在本實施例中,該檢驗系統S3係為一檢驗資訊系統(LIS)。
The inspection system S3 is coupled to the cloud server C, and the inspection information S3 is used to generate inspection reports such as the dyeing report, the preliminary report, and the final report, and pass the dyeing report, the preliminary report and the final report through the cloud The server C sends to the antibiotic selection notification system S1, or can be input to the antibiotic selection notification system S1 through an external access medium, and displayed on the man-
綜上所述,本發明的抗生素選用通知系統及具有該系統的醫療管理系統,係能夠在該人機介面單元接收到病人之最終報告時,判斷該病人使用中之抗生素是可能適當的,並藉由整合該染色對應表、該初步對應表及該分階對應表,取得抗生素級別低於該抗生素且具有可能適當效果的一替代抗生素,該處理單元依據該無線傳輸單元,將該替代抗生素的名稱發送至醫師的聯鉻裝置,以供醫師將該病人使用中之抗生素調整為該替代抗生素。如此,本發明係可以達到縮短病人之檢驗報告發出至醫師調整用藥的時間差、降低誘發致病菌抗藥性細菌產生之機會、及提升醫療照護品質等功效。 In summary, the antibiotic selection notification system and the medical management system with the system of the present invention are capable of judging that the antibiotics being used by the patient may be appropriate when the human-machine interface unit receives the patient's final report, and By integrating the dyeing correspondence table, the preliminary correspondence table, and the graded correspondence table, a substitute antibiotic with an antibiotic grade lower than the antibiotic and possibly an appropriate effect is obtained, and the processing unit determines the substitute antibiotic's value according to the wireless transmission unit. The name is sent to the doctor's bichromium device for the doctor to adjust the antibiotic used by the patient to the substitute antibiotic. In this way, the present invention can shorten the time lag between the issuance of the patient's test report and the doctor's adjustment of medication, reduce the chance of inducing the generation of pathogenic bacteria and drug-resistant bacteria, and improve the quality of medical care.
雖然本發明已利用上述較佳實施例揭示,然其並非用以限定本發明,任何熟習此技藝者在不脫離本發明之精神和範圍之內,相對上述實施例進行各種更動與修改仍屬本發明所保護之技術範疇,因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。 Although the present invention has been disclosed using the above-mentioned preferred embodiments, it is not intended to limit the present invention. Anyone who is familiar with the art without departing from the spirit and scope of the present invention may make various changes and modifications relative to the above-mentioned embodiments. The technical scope of the invention is protected. Therefore, the scope of protection of the invention shall be subject to the scope of the attached patent application.
1:資料庫單元 1: Database unit
2:人機介面單元 2: Human-machine interface unit
3:無線傳輸單元 3: Wireless transmission unit
4:處理單元 4: Processing unit
UI:使用者介面 UI: User interface
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW109127953A TWI729911B (en) | 2020-08-17 | 2020-08-17 | Antibiotic selection notification system and medical management system including the notification system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW109127953A TWI729911B (en) | 2020-08-17 | 2020-08-17 | Antibiotic selection notification system and medical management system including the notification system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TWI729911B true TWI729911B (en) | 2021-06-01 |
| TW202209342A TW202209342A (en) | 2022-03-01 |
Family
ID=77517439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109127953A TWI729911B (en) | 2020-08-17 | 2020-08-17 | Antibiotic selection notification system and medical management system including the notification system |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI729911B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130325502A1 (en) * | 2012-06-05 | 2013-12-05 | Ari Robicsek | System and method for providing syndrome-specific, weighted-incidence treatment regimen recommendations |
-
2020
- 2020-08-17 TW TW109127953A patent/TWI729911B/en active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130325502A1 (en) * | 2012-06-05 | 2013-12-05 | Ari Robicsek | System and method for providing syndrome-specific, weighted-incidence treatment regimen recommendations |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202209342A (en) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Widmer et al. | Duration of treatment for asymptomatic bacteriuria during pregnancy | |
| Nace et al. | Clinical uncertainties in the approach to long term care residents with possible urinary tract infection | |
| Finkelstein et al. | Reducing antibiotic use in children: a randomized trial in 12 practices | |
| Mangham et al. | Malaria prevalence and treatment of febrile patients at health facilities and medicine retailers in Cameroon | |
| CN111223534B (en) | Industry and financial fusion fine management system | |
| Teagarden | Meta‐analysis: whither narrative review? | |
| CN103854136A (en) | Hospital medication management system with medication safety monitoring and intervening functions | |
| CN105893725A (en) | Management system for an entire process of hospital infection prevention and control, and method thereof | |
| Yin et al. | Comparing automated vs. manual data collection for COVID-specific medications from electronic health records | |
| Lima et al. | Transforming two decades of ePR data to OMOP CDM for clinical research | |
| CN102004863A (en) | Clinical safe and reasonable administration decision supporting method | |
| CN102012974A (en) | Clinical safe and rational administration decision support system | |
| CN114580007A (en) | Medical data desensitization methods and apparatus | |
| CN111755132B (en) | Information management system | |
| CN106909796A (en) | Infectious disease actively monitoring early warning system in a kind of medical institutions | |
| Street et al. | Introduction: Diagnostics, medical testing, and value in medical anthropology | |
| CN111696639A (en) | Patient health big data self-management system and method thereof | |
| Yang et al. | Application of Donabedian Three‐Dimensional Model in Outpatient Care Quality: A Scoping Review | |
| Valia et al. | Use of WATCH antibiotics prior to presentation to the hospital in rural Burkina Faso | |
| Meloncelli et al. | Gestational diabetes mellitus screening and diagnosis criteria before and during the COVID‐19 pandemic: a retrospective pre–post study | |
| Zhang et al. | The present and future of digital health, digital medicine, and digital therapeutics for allergic diseases | |
| TWI729911B (en) | Antibiotic selection notification system and medical management system including the notification system | |
| CN108831534A (en) | Tuberculosis total management system and mobile APP project | |
| Feng et al. | Development and psychometric testing of a questionnaire to assess Nurse’s perception of risks during enteral nutrition | |
| Chen et al. | Development and Application of a Multidrug-Resistant Tuberculosis Case Management System—Yunnan Province, China, 2017–2020 |